The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

Status unconfirmed · Phase 2

Conditions studied: Treatment Resistant Depression

In brief

The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.

Key facts

Study ID

NCT04433845

Run by

Sheppard Pratt Health System

People needed

15

Starts

2021-03-01

Expected to finish

2023-04-15

Last updated by the study team

2022-10-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Type 2 Bipolar Disorder (BP-II) Depression

You may not qualify if…

• Comorbidities

Where it is running

• Sheppard Pratt — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.